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Abstract: Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare prion disease that causes 
rapidly progressive fatal neurodegeneration. The rarer Heidenhain variant of sCJD presents 
with visual symptoms and is rarely reported in the literature from sub-Saharan Africa. We 
report the case of a 57-year-old male with a three-week history of losing direction when 
driving home and visual hallucinations described as seeing rainbows. Magnetic resonance 
imaging (MRI) of the brain revealed unilateral parieto-occipital sulcal hyperintensities with 
restriction on diffusion-weighted imaging (DWI), and electroencephalography (EEG) 
showed right para-central slowing leading to an initial diagnosis of non-convulsive status 
epilepticus. He was treated with anti-epileptic medication but was re-admitted less than 
a month later with worsening spatial memory, aggression, ataxia, dysarthria, myoclonic jerks 
and a positive startle response, later developing generalised tonic-clonic seizures. Repeat 
MRI brain scan showed widespread posterior-predominant sulcal DWI restriction in 
a cortical ribboning pattern pathognomonic for sCJD. EEG showed diffuse slowing, and 
cerebrospinal fluid was analyzed for abnormal prion protein using real-time quaking-induced 
conversion but was inconclusive due to suboptimal sample collection. The patient fulfilled 
the diagnostic criteria for probable sCJD, Heidenhain variant; the family declined brain 
biopsy for definitive diagnosis. He was subsequently palliated at a local hospice where he 
died approximately three months after the onset of symptoms. Our case highlights the 
presence of a rare form of sCJD, and the diagnostic challenges faced in our resource- 
limited setting. 
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Introduction
Creutzfeldt-Jakob disease is a rare prion disease characterized by transmissible 
spongiform encephalopathy resulting in rapidly progressive and invariably fatal 
neurodegeneration. Eighty-five percent of cases occur as sporadic Creutzfeldt-Jakob 
disease (sCJD).1 The classical presentation of sCJD is of a rapidly progressive 
dementia with myoclonus and seizures; other non-cognitive neurological symptoms 
can also occur early on, e.g. cerebellar ataxia, psychiatric symptoms, stroke-like 
episodes and extrapyramidal symptoms.1 Visual disturbances at onset, reflecting 
early posterior cortical involvement, occur in 4.9% of sCJD cases, termed the 
Heidenhain variant.2 Given the myriad of presentations, it is important to exclude 
mimics and chameleons of sCJD during the diagnostic work-up.3 The clinical 
picture, tissue analysis [including cerebrospinal fluid (CSF)], electroencephalogra-
phy (EEG), and brain magnetic resonance imaging (MRI) are all required for 
fulfilling the international diagnostic criteria.4 Definitive diagnosis of sCJD is 
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made by histopathologic examination through post- 
mortem autopsy or ante-mortem biopsy.4
The annual incidence of sCJD is approximately 1 -
per million population, but the epidemiology of sCJD is 
poorly reported outside Europe, Australia and North 
America.5 From the African continent, there are only 
a few reported cases from North,6 West,7 and East8 
Africa, with one iatrogenic case from South Africa.9 Out 
of the 18 published cases from Africa, only 2 had MRI 
brain imaging, of which none showed pathognomonic 
changes, and none of the patients were reported to present 
with the Heidenhain variant of sCJD.
Materials and Methods
We present the first reported case of the Heidenhain variant 
of sCJD from the East Africa region, who was referred to 
our regional tertiary neurology referral center in Nairobi.
Case Presentation
A 57-year-old male was admitted to our facility with 
a three-week history of visual hallucinations described as 
seeing rainbows, and losing direction when driving home. 
The family also reported a recent history of impaired 
short-term memory. He was known to have stable long- 
standing type 2 diabetes and hypertension. The patient had 
no past history of corneal grafting, dura mater transplanta-
tion, or pituitary growth hormone treatment, and there was 
no family history of dementia or rapid cognitive decline.
Full neurological examination revealed a left incongruous 
homonymous hemianopia, confirmed on formal ophthalmol-
ogy review. Montreal cognitive assessment score was abnor-
mal at 15/30 (normal >25/30). MRI brain scan (Figure 1) 
revealed restriction on diffusion weighted imaging (DWI) of 
the right precuneus, and bilateral but right-predominant par-
ietal cortices. EEG was suggestive of paracentral slowing 
with no periodic sharp wave complexes. Laboratory investi-
gations including CSF analysis were all normal. He was 
diagnosed with non-convulsive status epilepticus and dis-
charged on levetiracetam, and was to be followed up in clinic.
However, the patient was readmitted after four weeks 
with significantly worsening spatial memory, aggression 
with persecutory delusions, and reduced mobility. On repeat 
neurological examination he was confused and speaking in 
short gibberish phrases, and had now also developed spasti-
city in all limbs. He could not walk due to apraxia and 
ataxia, and had myoclonic jerks with a positive startle 
response, but no signs of hepatic decompensation. Repeat 
MRI brain scan (Figure 2) now showed symmetrical and 
more widespread restriction on DWI in bilateral parieto- 
temporal lobes, giving the “cortical ribboning” appearance 
pathognomonic of sCJD. We therefore proceeded to inves-
tigate the patient for diseases that mimic sCJD,3 all of which 
were normal or negative. Table 1 summarizes all the inves-
tigations done on the patient during both admissions.
Repeat EEG revealed diffuse slowing again without 
periodic sharp waves. We treated for reversible causes 
with high-dose intravenous methylprednisolone over 
three days and re-loaded with intravenous levetiracetam 
and phenytoin, but there was no positive change noted in 
his clinical condition. He continued to deteriorate whilst in 
hospital and developed generalised tonic-clonic seizures 
and soon became mute and doubly incontinent. We made 
the diagnosis of sCJD, likely the Heidenhain variant given 
the predominant visual presentation, and invited two 
further independent neurologists to review his case who 
both agreed with the diagnosis. For confirmation, we 
Figure 1 MRI brain on first admission. (A) (diffusion weighted imaging, DWI) and (B) (apparent diffusion coefficient, ADC): right > left restricted diffusion of parietal lobe 
(open arrows). (C) (fluid-attenuated inversion recovery, FLAIR): hyper-intense signal in right precuneus and parietal lobe (closed arrow), sparing white matter.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                               
International Medical Case Reports Journal 2021:14 40








































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
discussed with the family about brain biopsy who opted 
against it, but agreed to send CSF overseas for real-time 
quaking-induced conversion (RT-QuIC) analysis to detect 
the abnormal prion protein.10 The results came back nega-
tive for the first admission sample, and inconclusive for 
the second admission sample, attributed to the storage and 
collection of the samples.
Given the rapid deterioration in the patient’s condition, 
we involved the palliative team soon after establishing 
a clinical probable diagnosis of sCJD, and managed him 
with regular levetiracetam for seizures, clonazepam for 
myoclonus and risperidone for aggression. He was subse-
quently transferred to a hospice near his home where he 
died approximately three months after the onset of 
symptoms.
Discussion
Our patient’s clinical presentation fulfilled the criteria for 
Heidenhain variant of sCJD given the isolated visual dis-
turbance at the onset of disease, cortical ribboning on MRI 
and his rapid clinical decline.2,4,11 Other visual presenta-
tions reported in literature include blurred vision, visual 
field restriction, disturbed color perception, cortical 
blindness,11 and even “Alice in Wonderland” syndrome 
consisting of visual metamorphopsias.12 There are reports 
of non-specifically altered vision associated with depres-
sive symptoms but being mistaken for a primary psychia-
tric disease instead of sCJD.13
The pathognomonic MRI findings in the Heidenhain 
variant of sCJD are the DWI cortical ribboning appear-
ances involving the occipital lobes;14 temporal and parietal 
lobe involvement without basal ganglia signal change, as 
seen in our patient’s neuro-imaging, have also been 
described.15 The differential diagnoses for these MRI 
abnormalities are relatively narrow,16 which we investi-
gated in our diagnostic work-up as per Table 1. The typical 
EEG findings of periodic sharp waves develop later in 
disease, so may not be picked up in the Heidenhain variant 
as it tends to have a sharper decline; if found, the EEG 
abnormalities tend to be more posterior predominant.11
The RT-QuIC test is part of the guidelines for diagnosing 
sCJD.4,10 It detects abnormal prion protein and has >95% 
sensitivity and specificity. In our patient’s case, the first 
admission sample was taken very early on from disease 
onset, and had been kept in normal storage conditions (refri-
gerated at 4°C) for more than eight days; the second admis-
sion sample had 1500 red cells/mm3 due to a traumatic spinal 
tap, which also resulted in raised protein (0.59 g/dL, normal 
range 0.25–0.45). All these factors are known to lead to false 
negative RT-QuIC results.10 We have since introduced 
a standardized protocol in our hospital on CSF investigations 
in suspected sCJD, with stipulations on storage at −80°C, 
analysis within eight days of sample collection, and repeat 
sampling if the CSF has high protein content and/or high red 
or white cell counts. We have also mandated analysis of 14- 
3-3 and tau proteins as a standard panel in addition to RT- 
QuIC in such cases.
Definitive diagnosis of sCJD requires histopathologic 
examination through post-mortem autopsy or ante-mortem 
biopsy.4 We did not proceed to biopsy due to family 
wishes as well as a joint decision we made with our 
neurosurgical team given the risk of contaminating or 
indefinitely quarantining scarce neurosurgical equipment. 
Our patient had probable sCJD, and as per the diagnostic 
criteria we also had to exclude other mimicking secondary 
causes, investigations for which we followed published 
Figure 2 MRI brain on second admission one month later. (A) (DWI) (B) (ADC) and (C) (FLAIR): Bilateral symmetrical parietal cortical FLAIR hyperintense signals with 
restricted diffusion (open arrows) more marked in the parafalcine regions (closed arrow).
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Table 1 Investigations Performed to Exclude Mimics and Chameleons of CJD3
Differential Diagnosis for sCJD Clinical and/or Laboratory Basis for Exclusion of Diagnosis
Auto-immune encephalitides including CNS lupus ● No recorded fever
● No pathognomonic movement disorders (dyskinesia in anti-NMDA, 
facio-brachial dystonic seizures in anti-VGKC)
● Negative for ANA, ANCA, anti-dsDNA, anti-NMDA, anti-VGKC, anti- 
GAD antibodies including in CSF
Primary rapidly progressive neurodegeneration including 
mitochondrial disease, or delirium in the context of 
neurodegeneration
● No antecedent history suggestive of underlying neurodegeneration e.g. 
frontotemporal dementia
● MRI brain findings not compatible with dementia diagnosis
● No intercurrent illness (electrolyte disturbance, infection) found in 
blood or urine
● Normal CSF lactate levels
Neuro-inflammatory conditions including CNS vasculitis and 
sarcoidosis
● Normal inflammatory markers including ESR, CRP and complement 
(C3, C4); normal serum angiotensin converting enzyme levels
● Normal CSF findings
● Normal CT chest and abdomen
● Contrast-enhanced MRI brain with angiography not in keeping with 
CNS vasculitis or lymphoma
● No response to intravenous methylprednisolone treatment
Neurotoxicity syndromes including heavy metal exposure and hypoxic 
encephalopathy
● Serum lead, lithium and mercury levels not checked as no compatible 
occupational or exposure history according to the patient’s family
● Clinical history and examination not in keeping with hypoxic injury
Neurological malignancy including gliomatosis cerebri, carcinomatous 
meningitis, CNS lymphoma
● Normal CSF findings x2
● Normal CT chest and abdomen
● Patient’s family could not afford PET/CT scan at the time
CNS infections ● Negative serology for HIV, syphilis, cytomegalovirus; no fungi seen on 
CSF staining
● Lyme’s disease is not endemic in Kenya therefore not tested and patient 
had no history of travel
● Pure sulcal involvement on MRI, and no evidence of immunosuppres-
sion excluded PML therefore JC virus not tested in CSF
● Measles in CSF not tested as sparing of white matter in MRI brain 
findings excluded SSPE
● Whipple’s disease was not investigated for, but MRI brain findings were 
not classical and patient had no gastro-intestinal symptoms
Metabolic, electrolyte, endocrine, hepatic and hematinic disturbances 
including subacute combined degeneration and extra-pontine 
myelinolysis
● Patient did not have a history of alcohol use.
● Normal full blood count, urea, electrolytes including sodium and potas-
sium, calcium, magnesium, vitamin B12, folic acid, complete thyroid 
function including TSH, HBA1c, random blood glucose, liver function 
tests, hepatitis B, hepatitis C serology
● No sudden change in electolytes
● Serum ammonia levels not available in our laboratory, but normal LFTs 
and liver imaging excluded hyperammonemia as a cause
Functional/psychiatric disorders ● Abnormal MRI brain scan and EEG
Abbreviations: ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; CNS, central nervous system; CRP, C-reactive protein; CSF, cerebrospinal fluid; 
CT, computed tomography; EEG, electroencephalography; ESR, erythrocyte sedimentation rate; HBA1c, glycosylated haemoglobin; GAD, glutamic acid decarboxylase; MRI, 
magnetic resonance imaging; NMDA, anti-N-methyl-D-aspartate receptor; PET, positron emission tomography; PML, progressive multifocal leukoencephalopathy; sCJD, 
sporadic Creutzfeldt-Jakob disease; SSPE, subacute sclerosing pan-encephalitis; TSH, thyroid stimulating hormone; VKGC, voltage-gated potassium channel.
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recommendations.3 Important differentials such as infec-
tive and auto-immune encephalitis are a part of our stan-
dard work-up in such cases,17 whilst keeping in mind that 
false positive results can occur in sCJD (for example, 
encephalitis mediated by antibodies against glutamic acid 
decarboxylase,18 which were negative in our patient). We 
could not perform genetic analysis of the PRNP gene 
locally due to unavailability of the test, although the lack 
of a similar condition having occurred in a first-degree 
relative made familial prion disease less likely.4 Given 
the visual-onset presentation and the rapid decline it is 
likely our patient would have been homozygous for the 
MM1 subtype at codon 129.19 We have since instituted 
PRNP genetic testing through an outsourced laboratory.
The majority of sCJD patients die within one year of 
onset of symptoms, and the Heidenhain variant confers 
a more devastating course, with death usually within a few 
months of symptom onset,20 as demonstrated in our patient. 
The treatment of sCJD remains supportive, and we found 
early referral to palliative care was important for end-of-life 
management for the patient and his family.
Conclusion
Our case highlights:
● The challenges associated with the diagnosis of 
sCJD, especially the Heidenhain variant.
● The need to look for reversible causes in the differ-
ential of sCJD.
● sCJD remains a rare condition in sub-Saharan Africa, 
and although reported worldwide, adds to the few 
published cases from our region.
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